FILLUNAR

What this means for you

Approved and waiting on proof of use. It will register unless the applicant drops it, and its 13 May 2025 filing date already counts against anyone who files later.

Record

Serial number

79428897

Mark type

Stylized text

Filed

13 May 2025

Published for opposition

14 Apr 2026

Attorney of record

Brian P. Gregg

Goods and services

• Class 005 — Pharmaceuticals: Antiseptic preparations; medical hyaluronic acid in ampoule form for pharmaceutical purposes; drug delivery agents in the form of lyophilized formulations that facilitate the delivery of pharmaceutical preparations for the treatment of facial wrinkles and volume enhancement; medical preparations for the treatment of skin wrinkles and facial volume loss using drug delivery systems; chemical preparations for pharmaceutical use, namely, for skin wrinkles and facial volume loss using drug delivery systems; cells for medical purposes; reagents for medical use; pharmaceutical preparations for the treatment of skin wrinkles and facial volume loss using drug delivery systems; diagnostic preparations for medical purposes; medical anti-aging serum; viscous fillers for wrinkle filling or volume augmentation being medical skin grafts; nucleic acid for medical purposes; medical hyaluronic acid preparations for pharmaceutical purposes; pharmaceutical skin lotions; pharmaceutical preparations for skin wrinkles and facial volume loss using drug delivery systems; surgical transplants comprising living tissues; pharmaceutical preparations for the treatment and prevention of skin wrinkles and facial volume loss using drug delivery systems; natural biomaterials for tissue recovery for medical purposes; pharmaceutical preparations for the treatment of wrinkles; injectable medical preparations for wrinkle filling in the form of gels; injectable dermal fillers for the treatment of wrinkles in the form of gels; injectable dermal fillers; injectable pharmaceuticals for treatment of skin wrinkles and facial volume loss using drug delivery systems; injectable dermal fillers for the treatment of forehead lines, glabellar lines, temple lines, cheek volume loss, cheekbone volume loss, nasolabial folds lines, marionette lines, lip lines; pharmaceutical preparation for skin care; bandages for skin wounds; pharmaceutical preparation for scar treatment

Owner

• BIONT Co., Ltd., KR

Prosecution history

• 18 Mar 2026 — APPROVED FOR PUB - PRINCIPAL REGISTER
• 18 Mar 2026 — TEAS/EMAIL CORRESPONDENCE ENTERED
• 18 Mar 2026 — CORRESPONDENCE RECEIVED IN LAW OFFICE
• 18 Mar 2026 — TEAS REQUEST FOR RECONSIDERATION RECEIVED
• 09 Feb 2026 — NOTIFICATION OF FINAL REFUSAL EMAILED
• 09 Feb 2026 — FINAL REFUSAL E-MAILED
• 09 Feb 2026 — FINAL REFUSAL WRITTEN
• 07 Jan 2026 — TEAS/EMAIL CORRESPONDENCE ENTERED
• 07 Jan 2026 — CORRESPONDENCE RECEIVED IN LAW OFFICE
• 07 Jan 2026 — TEAS RESPONSE TO OFFICE ACTION RECEIVED
• 05 Dec 2025 — REFUSAL PROCESSED BY IB
• 20 Nov 2025 — NON-FINAL ACTION MAILED - REFUSAL SENT TO IB
• 20 Nov 2025 — REFUSAL PROCESSED BY MPU
• 02 Oct 2025 — NON-FINAL ACTION (IB REFUSAL) PREPARED FOR REVIEW
• 01 Oct 2025 — NON-FINAL ACTION WRITTEN